Skip to main content
SpringerLink
Log in

Successful Imatinib Treatment of Cardiac Involvement of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia Followed by Severe Hepatotoxicity

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Imatinib is highly effective for the treatment of chronic eosinophilic leukemia (CEL) caused by the FIP1L1-PDGFRA fusion gene. However, its effectiveness for cardiac involvement of CEL has remained unclear. We describe a 46-year-old man with CEL treated with imatinib. Reverse transcriptase-polymerase chain reaction and sequencing analyses revealed a FIP1L1-PDGFRA fusion transcript with FIP1L1 intron 10 fused to PDGFRA exon 12, and fluorescent in situ hybridization analysis confirmed the interstitial deletion in chromosome 4q12. On admission, the patient had left heart failure accompanied by a large thrombus in the left ventricle. After pretreatment with furosemide and prednisolone, we started imatinib treatment at 100 mg/day. Eosinophilia disappeared within 1 week, and the left ventricular thrombus was resolved within 5 months. At 6 months after starting imatinib, the patient showed grade 4 liver dysfunction. A liver biopsy revealed hepatocyte necrosis with lymphocyte infiltration. Fortunately, the FIP1L1-PDGFRA fusion transcript had become undetectable, and imatinib treatment was stopped. The liver dysfunction resolved within a month. Although the CEL relapsed 6 months later, imatinib could be successfully resumed in combination with 25 mg/day of prednisolone. Thus, imatinib may be very effective for treating the early cardiac involvement of FIP1 L1-PDGFRA—positive CEL, but it needs to be used cautiously.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214.

    Article  PubMed  CAS  Google Scholar 

  2. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473–478.

    Article  PubMed  CAS  Google Scholar 

  3. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. j Clin Gastroenterol. 2005;39:75–77.

    PubMed  CAS  Google Scholar 

  4. Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81:189–192.

    Article  PubMed  Google Scholar 

  5. Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91(suppl 6):ECR27.

    PubMed  Google Scholar 

  6. Ikuta K, Torimoto Y, Jimbo J, et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol. 2005;82:343–346.

    Article  PubMed  Google Scholar 

  7. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978–979.

    Article  PubMed  CAS  Google Scholar 

  8. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160–2161.

    Article  PubMed  CAS  Google Scholar 

  9. Robyn J, Lemery S, Philip McCoy J, et al. Multilineage involvement of the fusion gene in patients with FIP1 L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2006;132:286–292.

    Article  PubMed  CAS  Google Scholar 

  10. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA. 2003;100:7830–7835.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660–4666.

    Article  PubMed  CAS  Google Scholar 

  12. Rose C, Dupire S, Roche-Lestienne C, et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia. 2004;18:354–355.

    Article  PubMed  CAS  Google Scholar 

  13. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18:734–742.

    Article  PubMed  CAS  Google Scholar 

  14. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–2779.

    PubMed  CAS  Google Scholar 

  15. Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRα, classification by WHO criteria, and response to therapy with imatinib. Leuk Res. 2006;30:1201–1205.

    Article  PubMed  Google Scholar 

  16. La Starza R, Specchia G, Cuneo A, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica. 2005;90:596–601.

    Google Scholar 

  17. Musial J, Brzezinska-Kolarz B, Sanak M, Szczeklik A. Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib. Eur J Haematol. 2005;75:87–88.

    Article  PubMed  Google Scholar 

  18. Rotoli B, Catalano L, Galderisi M, et al. Rapid reversion of Loeffler’s endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma. 2004;45:2503–2507.

    Article  PubMed  CAS  Google Scholar 

  19. Lin NU, Sarantopoulos S, Stone JR, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455–3456.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, 113-8519, Tokyo, Japan

    Ayako Arai, Weihua Yan, Shihoko Wakabayashi & Osamu Miura

  2. Department of Molecular Cytogenetics, Medical Research Institute and School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, Japan

    Shin Hayashi & Johji Inazawa

Authors
  1. Ayako Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weihua Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shihoko Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shin Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johji Inazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayako Arai.

About this article

Cite this article

Arai, A., Yan, W., Wakabayashi, S. et al. Successful Imatinib Treatment of Cardiac Involvement of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia Followed by Severe Hepatotoxicity. Int J Hematol 86, 233–237 (2007). https://doi.org/10.1532/IJH97.07032

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.07032

Key words

Search

Navigation